Strategic leadership Target their recently expanded leadership team for partnerships and channel collaboration. With new VP roles in Strategic Development, Commercial Operations, and Marketing, there are more senior decision-makers to engage on joint go-to-market strategies and to pilot compatible NO delivery solutions in hospital settings.

Hospital appetite Position Genosyl DS and related iNO delivery platforms as essential upgrades for acute care and neonatal units. Their focus on cardiopulmonary conditions and expansion into operating room rebreathing anesthesia suggests opportunity to upsell integrated NO delivery systems, service agreements, and clinician training programs.

Financing signals Leverage their funded growth history and investor confidence to propose scalable deployment plans, phased procurement, and bundled financing options. The prior $100M and $30M financings indicate willingness to adopt capital-light or value-based purchasing arrangements for new generations of iNO technology.

Global expansion Explore international or cross-site deployments through hospital networks and GPOs, given their growth in hospital settings and neonatal focus. Offer regional implementation support, regulatory alignment assistance, and multi-site rollout playbooks to accelerate adoption across facilities.

Digital & training Capitalize on their tech stack and cloud footprint to propose integrated digital solutions, remote monitoring, and clinician training modules. Propose analytics, maintenance dashboards, and SaaS-enabled support to improve safety, compliance, and real-world outcomes, aligning with their emphasis on safety and efficacy.